DGAP-News

STADA Arzneimittel AG: STADA announces agenda for the Annual General Meeting 2016 - Seite 2

long-range future:

- Rolf Hoffmann (57), most recently a member of the expanded Executive
Board of Amgen, Senior Vice President of U.S. Commercial Operations at
Amgen Inc. and, since June 2016, an adjunct professor at the University
of North Carolina's Kenan-Flagler Business School in Chapel Hill, USA,
for strategy and international business development. In Mr. Hoffmann,
STADA will gain a proven pharmaceutical and biotech expert who
demonstrates comprehensive operational responsibility on all
continents. Mr. Hoffmann is experienced in the process of tapping and
expanding the world's largest pharmaceutical markets, including Brazil,
Russia, China and Japan.

- Dr. Birgit Kudlek (49), a member of the Supervisory Board of WILEX AG
and most recently the Chief Operating Officer of Aenova Holding GmbH.
Dr. Kudlek is a pharmacist, economist and a proven expert in the
generic drug industry. She also has many years of international
management experience in the areas of development, approval and
production. She has held managing positions for well-known generic
companies such as Sandoz, known by the name Hexal in Germany, and
Ratiopharm.

- Tina Müller (47), Director of Marketing and Chief Marketing Officer at
the Opel Group GmbH. Ms. Müller is one of Germany's most prominent
marketing and sales executives. In addition to the many years of work
she has done in the areas of consumer goods/fast-moving consumer goods,
she also has broad international know-how, including in the skin and
oral care segments important for STADA, through her previous activities
at Henkel, Wella and L'Oréal. She is also in charge of digitalization,
a relevant topic for STADA.

- Dr. Gunnar Riemann (58), an independent business consultant in the life
sciences industry and the former President (managing director) of the
global Environmental Science Division at Bayer CropScience AG. In Dr.
Riemann, STADA will gain an individual who is both a licensed
pharmacist with more than 30 years of experience in the international
life sciences industry and a highly respected expert for
pharmaceuticals, consumer care, biological products and animal health.
Dr. Riemann holds extensive international experience, including in the
US, Asia and South America. He was active for many years as a member of
the Executive Board of Bayer Schering Pharma and was responsible for
the integration after the takeover by Bayer. In addition, Dr. Riemann
can draw on extensive experience in the fields of production,
development, marketing and management in the OTC market, also a
relevant market for STADA.

The detailed resumés of the candidates are available on the company's
website. The candidates will also introduce themselves personally at the